Home
THURSDAY, JULY 6, 2017
Welcome Remarks by Lawrence Serfaty (FR)
Inauguration Address by Stanislas Pol (FR)
SESSION 1 • NASH IN OTHER SETTINGS
Chairs: Arun Sanyal (US) and Patrick Marcellin (FR)
NASH in HIV: how big is the problem?
Maud Lemoine (UK)
Are the therapeutic targets for NASH in HIV the same as in garden-variety NASH?
Richard Sterling (US)
The burden of NASH before and after liver transplantation
Rajender Reddy (US)
Is NASH responsible for disease progression after SVR in subjects with HCV?
Lawrence Serfaty (FR)
SESSION 2 • GETTING TO THE HEART OF THE MATTER
Chairs: Bruno Vergès (FR) and Ariel Cohen (FR)
Atherogenic risk factors and cardiac outcomes in NASH
Raluca Pais (FR)
NASH and the myocardium
Mohammad Siddiqui (US)
QTc and NASH-from molecular biology to clinical significance
Franck Boccara (FR)
SESSION 3 • CLINICAL HOT TOPICS
Chairs: Mohammad Siddiqui (US) and Philippe Mathurin (FR)
Disease burden report for Europe
Homie Razavi (US)
Prospective assessment of disease evolution in NASH
Arun Sanyal (US)
DILI phenotypes and its assessment in NASH
Robert Fontana (US)
SESSION 4 • THE ROLE OF THE GUT IN NASH
Chairs: Lawrence Serfaty (FR) and Gyongyi Szabo (US)
Plasticity of the mucosal barrier: Insights into regulation of the Intestinal Epithelial Barrier and Steatohepatitis
Asma Nusrat (US)
Endocrine signaling from the gut and its implications for NASH
Bart Staels (FR)
Impact of macronutrient constituents of diet on NASH phenotype and outcomes
Jean-Francois Dufour (CH)
Diet-microbiome interactions and NASH
Puneet Puri (US)
SESSION 5 • INFLAMMATION
Chairs: Alexandre Louvet (FR) and Stanislas Pol (FR)
Gut derived activators of inflammation in NASH
Gyongyi Szabo (US)
Intrahepatic intracellular activators of innate immunity in NASH
Wajahat Mehal (US)
Role of macrophages in disease development and progression
Frank Tacke (DE)
Adipose tissue inflammation in type 2 diabetes and NASH
Karine Clement (FR)
SESSION 6 • TECHNOLOGIC INNOVATIONS IN NASH
Chairs: Rohit Loomba (US) and Jean-Pierre Bronowicki (FR)
Hijacking the microbiome to modify NASH
Dean Falb (US)
Endoscopic treatment of Diabetes and NASH
Harith Rajagopalan (US)
Nanoparticle based anti-fibrotic therapies in NASH
Wenbin Ying (US)
The Copper - NAFLD connection: Role of hepatic copper deficiency
Peter Ferenci (AT)
FRIDAY, JULY 7, 2017
SESSION 7 • INNOVATIONS IN FIBROSIS ASSESSMENT
Chairs: Pierre Bedossa (FR) and Scott Friedman (US)
New algorithms for assessment of fibrosis in NAFLD
Jérôme Boursier (FR)
Dual photon microscopy and its potential for assessing fibrosis evolution
Arun Sanyal (US)
Potential role of deuterated markers in assessment of fibrosis
Rohit Loomba (US)
Assessing fibrosis using antibodies to collagen epitopes
Morten Karsdal (DK)
SESSION 8 • SHORTENING TIMELINES AND IMPROVING EFFICIENCY IN DRUG DEVELOPMENT
Chairs: Mark DeLegge (US) and Dominique Larrey (FR)
Seamless drug development paradigms
Claudia Filozof (UK)
Point of Care tests for the diagnosis of NASH in clinical trials, design consideration and potential use
Karine Lacombe (FR)
Causality assessment in large data: potential applications for NASH
Antoine Chambaz (FR)
SESSION 9 • REGULATORY LANDSCAPE
Chair: Lawrence Serfaty (FR)
What is new on the regulatory front?
Veronica Miller (US)
WORKING LUNCHES SESSION
GROUP 1: Transatlantic Biomarker Development
Julia Brosnan (US) and Sudha Shankar (US)
GROUP 2: NASH cohorts for clinical trials around the world
Arun Sanyal (US) and Vlad Ratziu (FR)
GROUP 3: The place of bariatric surgery in NASH: can we extend the indications?
Philippe Mathurin (FR) and Nicolas Goossens (CH)
SESSION 10 • STATE OF THE ART LECTURE
Chair: Arun Sanyal (US)
Past, present and future of therapeutics for liver fibrosis
Scott Friedman (US)
Closing Remarks by Arun Sanyal (US)